Obesity associated with increased postmenopausal invasive breast cancer risk
the ONA take:
Obesity is associated with increased risk for invasive breast cancer in postmenopausal women, a new study published online ahead of print in JAMA Oncology has shown.
For the secondary analysis, researchers sought to investigate the associations of overweight and obesity with the risk of developing postmenopausal invasive breast cancer after a long follow-up in the Women's Health Initiative studies.
Researchers analyzed data from 67,142 postmenopausal women ages 50 to 79 years. Patients were followed for a median of 13 years. During that time, 3,388 patients were diagnosed with invasive breast cancers.
Results showed that women who were overweight and obese had an increased risk for developing invasive breast cancer compared with those of normal weight. Researchers found that women with a BMI of 35.0 or higher was strongly associated with risk of developing estrogen receptor-positive and progesterone receptor-negative breast cancers.
The findings suggest that more strategies should be developed to prevent obesity in postmenopausal women.
Obesity is associated with increased risk for invasive breast cancer in postmenopausal women.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|